SeekingAlpha · Sep 15, 2026
Sionna Therapeutics, Inc. (SION) Discusses Post-Hoc Analysis of PreciSION CF Trial and Advancement of Dual Combination Program - Slideshow
2026-09-15. The following slide deck was published by Sionna Therapeutics, Inc.
SI
NASDAQ · SION
Sionna Therapeutics, Inc.
Healthcare · Biotechnology
$5.96
Down-$1.22 (-16.99%)
Updated Sep 19, 2026, 4:02 AM
SID Score
3.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.86B
- P/E ratio
- -31.26
- Dividend yield
- 0.00%
- 52-week range
- $4.01 – $54.97
- Volume
- 3.7M
- Avg. volume
- 293.9K
Price performance
SION price history
1M range · 20 trading sessions · Daily adjusted prices
SION closed at $5.96 after 20 trading sessions, up 12.67% for the selected period.
- Last close
- $5.96
- Period change
- +12.67%
- Period low
- $5.29
- Period high
- $8.26
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $7.12 | $7.19 | $5.90 | $5.96 | 3.7M |
| Sep 17, 2026 | $7.27 | $7.73 | $7.15 | $7.18 | 1.48M |
| Sep 16, 2026 | $6.95 | $7.3681 | $6.91 | $7.04 | 1.97M |
| Sep 15, 2026 | $7.87 | $8.00 | $6.85 | $6.88 | 2.46M |
| Sep 14, 2026 | $7.84 | $8.535 | $7.84 | $8.26 | 1.22M |
| Sep 11, 2026 | $7.79 | $8.03 | $7.47 | $7.85 | 1.21M |
| Sep 10, 2026 | $7.40 | $7.75 | $7.12 | $7.62 | 1.22M |
| Sep 9, 2026 | $7.27 | $7.55 | $7.1691 | $7.48 | 767.46K |
| Sep 8, 2026 | $7.13 | $7.555 | $6.89 | $7.30 | 884.75K |
| Sep 4, 2026 | $6.68 | $7.22 | $6.62 | $7.18 | 926.07K |
| Sep 3, 2026 | $7.31 | $7.56 | $6.70 | $6.75 | 1.24M |
| Sep 2, 2026 | $6.63 | $7.35 | $6.27 | $7.31 | 1.59M |
| Sep 1, 2026 | $5.95 | $6.48 | $5.93 | $6.46 | 1.41M |
| Aug 31, 2026 | $5.87 | $6.08 | $5.75 | $6.03 | 1.38M |
| Aug 28, 2026 | $5.97 | $6.06 | $5.8224 | $5.87 | 784.79K |
| Aug 27, 2026 | $6.14 | $6.2499 | $5.97 | $6.06 | 775.76K |
| Aug 26, 2026 | $6.20 | $6.29 | $6.02 | $6.17 | 926.26K |
| Aug 25, 2026 | $5.60 | $6.30 | $5.58 | $6.25 | 1.97M |
| Aug 24, 2026 | $5.29 | $5.61 | $5.21 | $5.59 | 1.78M |
| Aug 21, 2026 | $5.54 | $5.72 | $5.27 | $5.29 | 1.94M |
Latest SION news
The latest Smart Investors Daily articles mentioning SION.
Stock researchCompany · Overview
SION research
Overview
Company profile and research snapshot.
Company profile
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $34.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 15, 2026 | Wedbush | Neutral | — |
| Aug 11, 2026 | Guggenheim | Neutral | — |
| Aug 11, 2026 | Wedbush | Neutral | — |
| Aug 10, 2026 | BTIG | Neutral | — |
| Aug 7, 2026 | Guggenheim | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 15, 2026
Wedbush Maintains Neutral on Sionna Therapeutics, Raises Price Target to $6
Wedbush analyst Laura Chico maintains Sionna Therapeutics (NASDAQ:SION) with a Neutral and raises the price target from $5 to $6.
SeekingAlpha · Sep 15, 2026
Sionna Therapeutics, Inc. (SION) Discusses Post-Hoc Analysis of PreciSION CF Trial and Advancement of Dual Combination Program Transcript
Sionna Therapeutics, Inc. (SION) Discusses Post-Hoc Analysis of PreciSION CF Trial and Advancement of Dual Combination Program September 14, 2026 4:30 PM...
Yahoo · Sep 14, 2026
Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial
Post hoc analyses of SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L consistent with NBD1 biological activity Dual combination Phase 2a trial expected to initiate in first quarter of 2027 46% workforce reduction and other cost-saving measures prioritize advancing the dual combination program and extend cash runway into the second half of 2029 Sionna to host conference call today at 4:30 p.m. ET WALTHAM, Mass., Sept. 14, 2026 (GLOBE NEWSWI
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
